Insider Buying: Guardant Health, Inc. (NASDAQ:GH) CEO Acquires 40,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH – Get Rating) CEO Amirali Talasaz purchased 40,000 shares of the business’s stock in a transaction that occurred on Monday, March 13th. The stock was bought at an average price of $25.66 per share, with a total value of $1,026,400.00. Following the completion of the purchase, the chief executive officer now owns 1,893,845 shares of the company’s stock, valued at approximately $48,596,062.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Guardant Health Stock Performance

NASDAQ GH opened at $28.26 on Friday. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -4.42 and a beta of 0.86. Guardant Health, Inc. has a twelve month low of $24.20 and a twelve month high of $77.72. The stock has a fifty day simple moving average of $29.55 and a 200 day simple moving average of $40.91. The company has a quick ratio of 5.90, a current ratio of 6.17 and a debt-to-equity ratio of 18.90.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Guardant Health by 0.8% in the third quarter. Vanguard Group Inc. now owns 8,915,566 shares of the company’s stock valued at $479,925,000 after purchasing an additional 74,247 shares during the period. Capital International Investors increased its holdings in Guardant Health by 71.0% in the first quarter. Capital International Investors now owns 5,081,624 shares of the company’s stock valued at $336,607,000 after purchasing an additional 2,110,240 shares during the period. Clearbridge Investments LLC increased its holdings in Guardant Health by 8.0% in the first quarter. Clearbridge Investments LLC now owns 3,354,024 shares of the company’s stock valued at $222,171,000 after purchasing an additional 247,486 shares during the period. Alliancebernstein L.P. grew its holdings in Guardant Health by 243.3% during the 4th quarter. Alliancebernstein L.P. now owns 2,515,992 shares of the company’s stock worth $68,435,000 after acquiring an additional 1,783,131 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 6.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,702,980 shares of the company’s stock worth $46,322,000 after acquiring an additional 108,381 shares during the period. 90.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on GH shares. BTIG Research cut their target price on Guardant Health from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Friday, February 24th. Morgan Stanley cut their target price on Guardant Health from $73.00 to $66.00 and set an “overweight” rating for the company in a research note on Monday, February 27th. Piper Sandler cut their target price on Guardant Health from $50.00 to $35.00 and set a “neutral” rating for the company in a research note on Friday, March 3rd. Bank of America upped their target price on Guardant Health from $65.00 to $70.00 in a research note on Friday, December 16th. Finally, Citigroup cut Guardant Health from a “buy” rating to a “neutral” rating and cut their target price for the stock from $60.00 to $33.00 in a research note on Thursday, March 9th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $57.64.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.